» Articles » PMID: 30842333

Humanized Mouse Model of HIV-1 Latency with Enrichment of Latent Virus in PD-1 and TIGIT CD4 T Cells

Abstract

Combination anti-retroviral drug therapy (ART) potently suppresses HIV-1 replication but does not result in virus eradication or a cure. A major contributing factor is the long-term persistence of a reservoir of latently infected cells. To study this reservoir, we established a humanized mouse model of HIV-1 infection and ART suppression based on an oral ART regimen. Similar to humans, HIV-1 levels in the blood of ART-treated animals were frequently suppressed below the limits of detection. However, the limited timeframe of the mouse model and the small volume of available samples makes it a challenging model with which to achieve full viral suppression and to investigate the latent reservoir. We therefore used an latency reactivation assay that allows a semiquantitative measure of the latent reservoir that establishes in individual animals, regardless of whether they are treated with ART. Using this assay, we found that latently infected human CD4 T cells can be readily detected in mouse lymphoid tissues and that latent HIV-1 was enriched in populations expressing markers of T cell exhaustion, PD-1 and TIGIT. In addition, we were able to use the latency reactivation assay to demonstrate that HIV-specific TALENs can reduce the fraction of reactivatable virus in the latently infected cell population that establishes , supporting the use of targeted nuclease-based approaches for an HIV-1 cure. HIV-1 can establish latent infections that are not cleared by current antiretroviral drugs or the body's immune responses and therefore represent a major barrier to curing HIV-infected individuals. However, the lack of expression of viral antigens on latently infected cells makes them difficult to identify or study. Here, we describe a humanized mouse model that can be used to detect latent but reactivatable HIV-1 in both untreated mice and those on ART and therefore provides a simple system with which to study the latent HIV-1 reservoir and the impact of interventions aimed at reducing it.

Citing Articles

NK cell depletion in bispecific antibody therapy is associated with lack of HIV control after ART interruption.

Sanchez-Gaona N, Perea D, Curran A, Burgos J, Navarro J, Suanzes P Commun Biol. 2025; 8(1):236.

PMID: 39953264 PMC: 11829058. DOI: 10.1038/s42003-025-07651-6.


Reprogramming human B cells with custom heavy-chain antibodies.

Rogers G, Huang C, Mathur A, Huang X, Chen H, Stanten K Nat Biomed Eng. 2024; 8(12):1700-1714.

PMID: 39039240 DOI: 10.1038/s41551-024-01240-4.


The Humanized Mouse Model: What Added Value Does It Offer for HIV Research?.

Baroncini L, Bredl S, Nicole K, Speck R Pathogens. 2023; 12(4).

PMID: 37111494 PMC: 10142098. DOI: 10.3390/pathogens12040608.


An Efficient Humanized Mouse Model for Oral Anti-Retroviral Administration.

Virdi A, Ho S, Seaton M, Olali A, Narasipura S, Barbian H Cells. 2023; 12(7).

PMID: 37048107 PMC: 10093470. DOI: 10.3390/cells12071034.


HIV-1 infected humanized DRAGA mice develop HIV-specific antibodies despite lack of canonical germinal centers in secondary lymphoid tissues.

Ollerton M, Folkvord J, Peachman K, Shashikumar S, Morrison E, Jagodzinski L Front Immunol. 2022; 13:1047277.

PMID: 36505432 PMC: 9732419. DOI: 10.3389/fimmu.2022.1047277.


References
1.
Schacker T, Little S, Connick E, GEBHARD K, Zhang Z, Krieger J . Productive infection of T cells in lymphoid tissues during primary and early human immunodeficiency virus infection. J Infect Dis. 2001; 183(4):555-62. DOI: 10.1086/318524. View

2.
Sogaard O, Graversen M, Leth S, Olesen R, Brinkmann C, Nissen S . The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo. PLoS Pathog. 2015; 11(9):e1005142. PMC: 4575032. DOI: 10.1371/journal.ppat.1005142. View

3.
Hill A, Rosenbloom D, Goldstein E, Hanhauser E, Kuritzkes D, Siliciano R . Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV. PLoS Pathog. 2016; 12(4):e1005535. PMC: 4847932. DOI: 10.1371/journal.ppat.1005535. View

4.
Honeycutt J, Wahl A, Archin N, Choudhary S, Margolis D, Garcia J . HIV-1 infection, response to treatment and establishment of viral latency in a novel humanized T cell-only mouse (TOM) model. Retrovirology. 2013; 10:121. PMC: 3826870. DOI: 10.1186/1742-4690-10-121. View

5.
Iglesias-Ussel M, Vandergeeten C, Marchionni L, Chomont N, Romerio F . High levels of CD2 expression identify HIV-1 latently infected resting memory CD4+ T cells in virally suppressed subjects. J Virol. 2013; 87(16):9148-58. PMC: 3754042. DOI: 10.1128/JVI.01297-13. View